Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Theralase Technologies ( (TSE:TLT) ) has shared an update.
Theralase Technologies announced that its interim clinical data on the light-activated Ruvidar™ for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ will be presented at the 2025 American Urological Association Annual Meeting. This data highlights the treatment’s safety and efficacy, offering a potential significant advancement in bladder cancer therapy for patients with limited options. The treatment has shown promising results, with some patients experiencing a durable response of three years or more, potentially revolutionizing the treatment landscape for bladder cancer and allowing patients to avoid radical cystectomy.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical-stage pharmaceutical company focused on the research and development of light, radiation, sound, and drug-activated small molecules. The company’s primary aim is to provide safe and effective treatments for various cancers, bacteria, and viruses.
YTD Price Performance: -9.09%
Average Trading Volume: 97,772
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$61.95M
Learn more about TLT stock on TipRanks’ Stock Analysis page.
